Table 2 The effect of presence non-communicable diseases on the prescript of tocilizumab in patients with COVID-19
Variables | Subgroups (no. of studies/sample size) | Pooled effect size (% 95 CI) | Heterogeneity assessment | ||||
|---|---|---|---|---|---|---|---|
RR | Lower CI | Upper CI | I square (%) | Q Test | P value | ||
Non-communicable diseases | Hypertension | 1.03 | 1.00 | 1.12 | 28.08 | 11.12 | 0.19 |
Diabetes mellitus | 0.83 | 0.72 | 0.95 | 0.00 | 7.00 | 0.54 | |
Obesity | 1.07 | 0.76 | 1.50 | 0.00 | 0.32 | 0.57 | |
Cardiovascular disease | 1.17 | 0.98 | 1.40 | 20.43 | 8.80 | 0.27 | |
Myocardial infraction | 0.69 | 0.32 | 1.45 | 81.99 | 5.55 | 0.02 | |
COPD | 0.88 | 0.43 | 1.80 | 0.00 | 1.61 | 0.66 | |
Asthma | 1.27 | 0.65 | 2.50 | 0.08 | 3.00 | 0.39 | |
Chronic kidney disorder | 0.97 | 0.63 | 1.50 | 25.59 | 5.38 | 0.25 | |
Malignancy | 1.14 | 0.65 | 2.00 | 0.00 | 0.82 | 0.84 | |
Chronic pulmonary disorder | 1.20 | 0.71 | 2.03 | 0.00 | 0.02 | 0.99 | |
Chronic liver disorder | 1.43 | 0.42 | 4.86 | 0.00 | 0.00 | 0.96 | |